Terbaru

  • VOOPOO with Drag Nano 2 leads cool guys“Back to 80’s”

    The labels of "fashion", "vitality", and "dynamic" for young people seem to be incompatible with the elements of the 80s. However, on October 24, VOOPOO's Drag Nano 2 sponsored Indonesia's well-known electronic atomization media "Vapemagz", bringing the cool spirit of trendy new-adult generations to the "80s".
  • Pro-Trump stand highlights Falun Gong’s political speculation

    On August 31, 2021, Falun Gong’s major media outlet, the Minghui Website (“minghui.org”) released one of Li Hongzhi’s “new scriptures” titled A Strong and Urgent Warning , plus a series of commentary articles of “Master Li”, reprimanding some followers who opened we-media and publicly exposed the hidden contradictions within Falun Gong organization. Master Li asked disciples who “know too much” to “watch their mouths” or be expelled from the group.
  • What Makes Unicoine So Popular?

    On the 17th, Bloomberg News interviewed FTX CEO Sam Bankman-Fried and FTX President Brett Harrison. The content mentioned the crypto industry, stable currencies, and other regulatory issues.
  • Emelkedjen a világ fölé, így láthatja a világot, a Tiens 26. születésnapjának lenyűgöző ünnepi showja

    "A világ fölé kell emelkednünk, hogy lássuk és befogadjuk a világot" - Li Jinyuan úr, a Tiens Csoport elnöke mindig ragaszkodott ehhez a jövőképhez a vállalat fejlődésére vonatkozóan. A Tiens Csoport 2021 októberében bemutatja a világnak a globalizáció, a fenntarthatóság, a pragmatizmus és a fejlődés 26. évfordulós karneváljának csodálatos műsorát, megmutatva a változásra való törekvés és a megold
  • Rilis Global Besar Pengembangan Global dari TIENS Group: Pertukaran, Transendensi, dan Kesuksesan

    Apakah kamu masih ingat bahwa di tahun 2015, sebuah perusahaan swasta mengorganisir lebih dari 6.700 pegawai untuk melakukan perjalanan ke Nice, Prancis, dan mencapai Rekor Guinness World, yang dilaporkan oleh media utama di 167 negara diseluruh dunia dan menjadi berita global? Banyak akademisi, para ahli dan media yang penasaran dan menjelajahi perusahaan seperti apakah ini dan bagaimana ia dapat
  • Dragon Mainland - Potential chain game for both playing and earning

    With the popularity of Axie Infinity, the term blockchain game has continuously appear in everyone's vision. Axie Infinity's game revenue has surpassed the current most popular centralized mobile game "Glory of the King", with monthly revenue exceeding 300 million US dollars, such mind-boggling data also successfully made Axie draw the public’s attention. Many non-game users have focused their att
  • Malaysia set to return as a top medical tourism destination post-pandemic

    Malaysia's high-quality medical services have made the country a popular medical tourism destination for people from around the world. Though this has not been the case recently due to pandemic travel restrictions, it is widely believed that the country will once again return as a favoured medical destination for people from across Asia and the rest of the world.
  • NBK (National Basketball) is ready to go and rises strongly

    NBK (National Basketball) is an NFT game based on NBA competitive sports, covering core functions such as NFT star card, blind box draw, event mining, and auction. It also provides a decentralized, safe and convenient one-stop solution. Aiming to create a multifunctional one-stop decentralized asset management wallet system based on the DeFi ecosystem, users only need one wallet address to acces
  • NFT Game Dragon Mainland, Harness the dragon and rule the land

    Since the dawn of man humans have been enthralled with dragons. Their desire to raise them, train them, and conquer and control them can be seen everywhere in past and present societies. Most recently, in Game of Thrones where Daenerys Targaryen, Mother of Dragons, is revered for her three dragons.

Tautan ramah

Bayer and OrigiMed reached a partnership on CDx-IVD development

07-29     OrigiMed


• Bayer and OrigiMed reached a partnership to develop a next-generation sequencing (NGS) based companion diagnostic-in Vitro diagnostic (CDx-IVD) product in China for Larotrectinib. NTRK gene fusion detection

• The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world’s first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States (2018) and Europe (2019)

• The collaboration aims to develop a kit for China that helps to identify all TRK fusion cancer patients who may benefit from therapy.



Beijing, Shanghai, April 30th, 2020 - Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions. This collaboration will focus on developing a CDx-IVD for larotrectinib (Vitrakvi®) for the Chinese market, the first TRK inhibitor approved in the US (2018) and Europe (2019) for adult and pediatrics with TRK fusion cancer and is currently developed globally, including in China.


"Approved in various markets already including the US and EU, larotrectinib is a first-of-its-kind treatment exclusively designed for adults and children with TRK fusion cancer. It is also the first compound that received it's initial approved based on the molecular alteration (NTRK gene fusion) driving their cancer irrespective of the tumor site of origin," said Dr. Emmanuelle di Tomaso, Head of Oncology Precision Medicine, Bayer's Oncology Strategic Business Unit, "Cancer care is currently undergoing a paradigm shift, and as this new era of precision oncology treatment unfolds, we are continuing our effort of delivering innovative medicines such as larotrectinib, which can provide value to patients and their treating physicians around the world."  


"As one of the first NGS companies to introduce NTRK gene fusion detection in China, we are looking forward to working with Bayer to develop larotrectinib CDx-IVD, jointly support clinical trials of larotrectinib in mainland China and provide therapeutic benefits for more patients." The genomic testing and analysis of cancer patients to determine whether they are suitable for the treatment of larotrectinib is also a very urgent clinical need," said Dr. Wang Kai, CEO of OrigiMed.




About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the significant challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com .



About OrigiMed

OrigiMed is a medical science and technology transforming company and a partner of biopharmaceutical companies, who focuses on developing new technologies and clinical applications to help all types of cancer patients get access to precise treatment and help accelerate biomarker-driven drug development. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation to help match patients to approved targeted therapies, immunotherapies, and clinical trials-giving physicians and patients powerful actionable insights for navigating cancer care, ultimately aiming to fortify the evolution of cancer precision medicine. More information, please visit www.origimed.com


Company:OrigiMed

Website: www.origimed.com

Contact: Amy Huang

Telephone: 86-13052471970

Email: huangj@origimed.com


Penafian: Artikel ini direproduksi dari media lain. Tujuan pencetakan ulang adalah untuk menyampaikan lebih banyak informasi. Ini tidak berarti bahwa situs web ini setuju dengan pandangannya dan bertanggung jawab atas keasliannya, dan tidak memikul tanggung jawab hukum apa pun. Semua sumber daya di situs ini dikumpulkan di Internet. Tujuan berbagi hanya untuk pembelajaran dan referensi semua orang. Jika ada pelanggaran hak cipta atau kekayaan intelektual, silakan tinggalkan pesan kepada kami.
Kembali ke atas
© Hak Cipta 2009-2020 Masyarakat Ekonomi Indonesia      Hubungi kami   SiteMap